Oncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview

Oncternal Therapeutics

06/11/2024 13:54

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 7 (estimated) for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
23.2% decrease in revenue to $137.5 thousand from $179 thousand
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Oncternal Therapeutics
Inc is
for a loss of $3.19 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is 20.50​, above​ its last closing price
of $1.62. ​​​

This summary was machine generated November 6 at 13:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)